RxDoctor Payments Data

Jessica Khabra, MD

Family Medicine · Fort Worth, TXNPI 1073178000

Payments from drug & device makers

$1,423in general payments, 2019–2025

Across 72 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$183
  • Sumitomo Pharma America, Inc.$173
  • Esperion Therapeutics, Inc.$117
  • Boehringer Ingelheim$113
  • Pfizer$100
  • Novo Nordisk$80
  • plus $658 from 24 others

What the payments were for

  • Food & beverage$1,423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,423 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$13,877
Medicare patients
63
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$68,037
EliquisApixaban50$50,757
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,864
MyrbetriqMirabegron13$14,372
XareltoRivaroxaban13$12,836
Aripiprazole36$9,110
Spiriva RespimatTiotropium Bromide12$8,014
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,315
Repatha SyringeEvolocumab13$7,153
Duloxetine Hcl106$6,922
Pregabalin68$3,411
Gabapentin106$3,256
Wixela InhubFluticasone Propion/Salmeterol18$3,227
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen152$3,207
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$80$68,03755 claims
PfizerEliquis$100$50,75750 claims
GSKTrelegy Ellipta, Anoro Ellipta$183$24,17939 claims
Astellas Pharma US IncMyrbetriq$15$14,37213 claims
Johnson & JohnsonXarelto$14$12,83613 claims
Boehringer IngelheimSpiriva Respimat$113$8,01412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →